ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 68 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $329 | -0.9% | 358,010 | +15.1% | 0.00% | 0.0% |
| Q1 2023 | $332 | -56.3% | 310,925 | -40.8% | 0.00% | -75.0% |
| Q4 2022 | $760 | -99.3% | 525,494 | +371.0% | 0.00% | +300.0% |
| Q3 2022 | $116,000 | +404.3% | 111,568 | +721.1% | 0.00% | – |
| Q2 2022 | $23,000 | -74.7% | 13,588 | -69.3% | 0.00% | – |
| Q1 2022 | $91,000 | -94.4% | 44,208 | -85.3% | 0.00% | -100.0% |
| Q4 2020 | $1,626,000 | +856.5% | 301,408 | +608.9% | 0.01% | +500.0% |
| Q2 2019 | $170,000 | +104.8% | 42,517 | +119.5% | 0.00% | – |
| Q1 2019 | $83,000 | -62.1% | 19,374 | -49.1% | 0.00% | -100.0% |
| Q4 2018 | $219,000 | -29.1% | 38,078 | +38.4% | 0.00% | 0.0% |
| Q1 2018 | $309,000 | +186.1% | 27,508 | +70.7% | 0.00% | – |
| Q4 2017 | $108,000 | -47.6% | 16,111 | -35.9% | 0.00% | -100.0% |
| Q3 2017 | $206,000 | – | 25,122 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 1,377,294 | $1,501,250 | 2.44% |
| NEA Management Company, LLC | 17,079,779 | $18,616,958 | 1.29% |
| Endurant Capital Management LP | 1,660,835 | $1,810,310 | 0.93% |
| Matrix Capital Management Company, LP | 38,974,185 | $42,481,862 | 0.58% |
| Long Focus Capital Management, LLC | 5,435,439 | $5,924,629 | 0.34% |
| PFM Health Sciences, LP | 5,992,571 | $6,531,902 | 0.29% |
| Key Client Fiduciary Advisors, LLC | 321,155 | $350,059 | 0.22% |
| DAFNA Capital Management LLC | 351,064 | $382,660 | 0.12% |
| Rock Springs Capital Management LP | 2,787,845 | $3,038,751 | 0.07% |
| Baker Brothers Advisors | 9,830,877 | $10,715,656 | 0.06% |